

Janssen Inc.

19 Green Belt Drive
Toronto, ON M3C 1L9
1.800.387.8781 toll free 416.449.9444 tel
416.449.2658 fax

www.janssen.ca



CONFIDENTIAL

March 21, 2016

BY FACSIMILE: 1 (250) 952-1584

Barbara Walman
Assistant Deputy Minister
Medical Beneficiary and Pharmaceutical Services
PO Box 9652
STN PROV GOVT
Victoria, BC
V8W 9P4

Dear Ms. Walman

Re: REMICADE® (Infliximab) Product Listing

I am writing to you with respect to the status of Janssen's infliximab product, REMICADE®, in the Province of British Columbia's PharmaCare program.

We understand from the BC PharmaCare Newsletter dated February 19, 2016 (Edition 16-001) that all requests for coverage of infliximab for infliximab-naïve patients for rheumatology and dermatology indications will be approved for the INFLECTRA® brand of infliximab only. The practical effect of this change is that REMICADE® is being excluded from the Province's PharmaCare program in favour of the new subsequent entry biologic ("SEB"), INFLECTRA® distributed by Pfizer and manufactured by Celltrion.

s.17

CONFIDENTIAL – NOT FOR DISCLOSURE

Page 02 to/à Page 03

Withheld pursuant to/removed as

s.17



s.17

Yours truly,

A handwritten signature in black ink that reads "Alaine C. Grand". The signature is written in a cursive, flowing style.

Alaine C. Grand
Vice-President, Law

cc. Eric Lun, Executive Director, Drug Intelligence and Optimization by fax: 1 (250) 952-2216
Kelly Uyeno, Executive Director, Business Management and Supplier Relations and Systems
by fax: 1 (604) 660-5405

CONFIDENTIAL – NOT FOR DISCLOSURE

Page 4 of 7

Page 05 to/à Page 07

Withheld pursuant to/removed as

s.17



April 8, 2016

1051149

Ms. Elaine Grand
Vice-President, Law
Janssen Inc.
19 Green Belt Dr
Toronto ON M3C 1L9

Dear Ms. Grand:

In response to your letter of March 21, 2016, I firmly disagree with your allegations. I'm confident that the Province of British Columbia has met all of our administrative and contractual obligations for this contract, including to ^{s.13,s.17}
^{s.13,s.17}

While I cannot agree with your position, I would still be open to meet with Janssen to discuss your concerns.

Sincerely,

Barbara Walman
Assistant Deputy Minister



Cc: Eric Lun, Drug Intelligence and Optimization
Kelly Uyeno, Business Management Supplier Relations, Systems

1055173

Janssen Inc.

19 Green Belt Drive
Toronto, ON M3C 1L9
1.800.367.8761 toll free 416.449.9444 tel
416.449.2658 fax

www.janssen.ca



May 2, 2016

Barbara Walman
Assistant Deputy Minister
Medical Beneficiary and Pharmaceutical Services
PO Box 9652
STN PROV GOVT
Victoria, BC
V8W 9P4

RE: **REMICADE® (infliximab) Product Listing**

Dear Ms. Walman,

We acknowledge receipt of your letter dated April 8th, 2016, with regards to the above matter.

As you are open to meeting with Janssen, I would like to bring Julia Brown, VP Access and Andy Williams, VP Immunology, to meet with you in person to discuss the concerns outlined in my letter dated March 21, 2016, and to determine whether s.13, s.17

* Derek Badger will follow-up with your office to schedule a mutually convenient date for a meeting.

We look forward to our discussion.

Yours truly,

Elaine C. Grand
VP Law

cc. Eric Lun, Executive Director, Drug Intelligence and Optimization by fax: 1 (250) 952-2216 → 1054531
Kelly Uyeno, Executive Director, Business Management and Supplier Relations and Systems → 1054531
by fax: 1 (604) 660-5405

MEETING MATERIAL

Cliff: 1055173

PREPARED FOR: Ms. Barbara Walman, Assistant Deputy Minister - Medical Beneficiary and Pharmaceutical Services Division (ADM - MBPSD), in order to prepare for a meeting with representatives of Janssen Inc. (Janssen) to be held July 12, 2016 2:00 p.m. to 3:00 p.m., at the Ministry of Health.

TITLE: Meeting between the ADM – MBPSD and Janssen to Discuss PharmaCare listing of Remicade[®] and Inflectra[®]

MEETING REQUEST/ISSUE: Janssen requested this meeting to discuss the issues they raised in their letter of March 21, 2016, and s.13,s.17

s.13,s.17

SHOULD MINISTRY STAFF ATTEND THIS MEETING?

The following Ministry staff should attend this meeting:

- Ms. Barbara Walman, ADM – MBPSD
- Mr. Eric Lun, Executive Director (ED) – Drug Intelligence and Optimization (DIO)
- Mr. Kelly Uyeno, ED – Business Management, Supplier Relations and Systems (BMSRS)

JANSSEN STAFF WHO WILL BE ATTENDING THE MEETING:

- Mr. Alain Grand, VP Law
- Ms. Julia Brown, VP Access
- Mr. Andy Williams, VP Immunology

BACKGROUND:

Janssen is a pharmaceutical company which produces a large number of drugs that receive PharmaCare coverage. One of these drugs, infliximab (Remicade[®]), a biologic indicated for rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), plaque psoriasis (PsO), ulcerative colitis (UC) and Crohn's disease (Crohn's), was the top drug in British Columbia in 2014/15 in terms of PharmaCare reimbursement.

The patent for Remicade[®] has expired and a Subsequent Entry Biologic (SEB), infliximab (Inflectra[®]), has entered the market. In 2014, Inflectra[®] was approved by Health Canada for RA, AS, PsA and PsO; however, its indications were expanded in June 2016 to include ulcerative colitis and Crohn's disease.

In 2014 and 2015, Inflectra[®] was reviewed by the Common Drug Review (CDR) and the Ministry. Based on these reviews, the Ministry decided, on February 19, 2016, to list only the Inflectra[®] brand of infliximab as a Limited Coverage benefit for the treatment of RA, AS, PsA and PsO for infliximab-naïve patients. Patients who received an initial Special Authority for infliximab before February 19, 2016, will be eligible for coverage of Remicade[®].

The CDR is currently reviewing Inflectra[®] for UC and Crohn's.

s.13,s.17

s.13,s.17

s.13,s.17

'the Province' s.13,s.17

s.13,s.17

On April 8, 2016, the ADM – MBPSD responded to Janssen in a brief letter stating, "I firmly disagree with your allegations."

FINANCIAL IMPLICATIONS:

The pan-Canadian Pharmaceutical Alliance (pCPA) and BMSRS were involved in negotiations with the manufacturer of Inflectra[®] which were successfully completed. s.13,s.17 has a significantly lower transparent list price for Inflectra[®], enabling savings for both public and private payers that can be reinvested into other priorities.

ADVICE:

The intended purpose of the meeting is to address Janssen's allegations that the Province s.13,s.17 which MBPSD strongly disagrees with. s.13,s.17

s.13,s.17

MEETING MATERIAL

Cliff #: 1098544

PREPARED FOR: Mr. Mitch Moneo, Assistant Deputy Minister (ADM), Pharmaceutical Services Division (PSD), for a meeting with Janssen Inc. (Janssen) personnel in New Westminster on January 12, 2018, from 11:00 am to noon.

TITLE: Meeting between the ADM and Janssen personnel, January 12, 2018 from 11:00am to 12:00pm

MEETING REQUEST/ISSUE: This meeting was requested by Mr. Derek Badger – Manager, Government Affairs (British Columbia), Janssen, who has suggested the following agenda:

1. Introductions
2. Overview of Janssen's operations, product pipeline and BC footprint
3. PSD priorities review and discussion
4. pan-Canadian Pharmaceutical Alliance (pCPA) update and discussion
5. Biosimilar policy update and discussion
6. Exploratory discussion on potential partnership framework(s)
7. Actions and follow-up consensus

Date requested: January 12, 2018, from 11:00 am to noon

Time required: One hour

Purpose of Meeting:

s.13,s.17

Meeting Material:

Janssen will provide a basic slide deck to leave behind as a reference material for Mr. Moneo that will cover the main points of their discussion. It will not be necessary to work off the materials at the meeting.

Desired location: New Westminster

Attendees: From Janssen:

Mr. Derek Badger – Manager, Government Affairs (BC)

Mr. Michael Debolt – Director, Government and Stakeholder Relations (Western Canada)

Ms. Julia Brown – Vice President, Government Affairs and Market Access (National)

SHOULD MINISTRY STAFF ATTEND THIS MEETING: Yes, the following should attend:

Mr. Mitch Moneo, ADM

Dr. Eric Lun, Executive Director – Drug Intelligence and Optimization

Mr. Kelly Uyeno, Executive Director – Business Management, Supplier Relations and Systems

BACKGROUND: Janssen is a pharmaceutical company (subsidiary of Johnson & Johnson), which conducts research and develops drugs in the fields of oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic disease.

The Ministry of Health (the Ministry) is currently reviewing five drugs manufactured by Janssen:

- canagliflozin (Invokana[®]) for Type 2 diabetes;
- canagliflozin-metformin (Invokamet[®]) for Type 2 diabetes;
- ustekinumab (Stelara[®]) for Crohn's disease;
- guselkumab (Tremfya[™]) for plaque psoriasis; and
- paliperidone (Invega Trinza[®]) for schizophrenia.

Janssen is the manufacturer of infliximab (Remicade), an innovator biologic indicated for rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriatic arthritis and plaque psoriasis. After Remicade's patent expired, two biosimilars became available: Renflexis[™], currently under review at the national Common Drug Review; and Inflectra[®], a Limited Coverage drug with preferential coverage for infliximab-naïve patients.

s.21

Biosimilars offer essentially identical products at significantly lower costs. Therefore, biosimilars are extremely important to the sustainability of our drug plan and our ability to fund other health priorities. For example, Inflectra costs about 50 percent less than Remicade for which the Product Listing Agreements have lapsed. In fiscal year 2015/16, PharmaCare and private payers spent over \$100 million on Remicade.

At the present time, BC PharmaCare's coverage policy for biosimilars does not require patients to switch from the more expensive innovator biologic to an equally effective but less expensive biosimilar. The Ministry is exploring options to transition patients from innovator biologics to biosimilars.

ADVICE: No specific topics need to be brought up or avoided. No materials need to be brought to the meeting.

From: Stuart Chatterley, Jo-Ann [JOICA]
To: [Walman, Barbara J. HLTH:EX](#)
Cc: [El Agab, Charlotte S HLTH:EX](#)
Subject: FW: Janssen Inc - follow up to our discussion of Oct. 6th
Date: Tuesday, October 20, 2015 9:33:51 AM
Attachments: [Biologics Proposal Outline - Janssen Inc. - October 5, 2015.pdf](#)
Sensitivity: Confidential

Hi Barb: Thanks for asking: Attached please find a confidential briefing note that Janssen has prepared and which I did share previously with DM Brown. Certainly please forward to others participating in the meeting. We will have a brief slide deck prepared to support this discussion, and should others be joining by teleconference we can send them the slides at the time if needed.

Also, I have just been informed that joining the meeting (from Janssen) will be Michael Debolt, Director, Government Affairs and Market Access, Western Canada.

Charlotte, I will forward the meeting invitation to Michael, however, one more question,.....will there be an LCD projector available? If not, Janssen will bring one.

Thanks

Jo-Ann

Jo-Ann Stuart Chatterley
Janssen Inc.
1.800.387.8781 ext 3018 toll free
604.541.9550 direct/604.541.9577 fax/604.765.9553 mobile
jschatt@its.jnj.com



From: "Walman, Barbara J. HLTH:EX" <Barbara.Walman@gov.bc.ca>
Date: October 19, 2015 at 4:33:34 PM PDT
To: "'Stuart Chatterley, Jo-Ann [JOICA]'" <jschatt@its.jnj.com>
Cc: "El Agab, Charlotte S HLTH:EX" <Charlotte.ElAgab@gov.bc.ca>
Subject: RE: Janssen Inc - follow up to our discussion of Oct. 6th

Thanks. Eric and Kelly may be joining me. Do you have any paperwork or documents

you'd like to share?

From: Stuart Chatterley, Jo-Ann [JOICA] [<mailto:jschatt@its.jnj.com>]
Sent: Monday, October 19, 2015 8:48 AM
To: Walman, Barbara J. HLTH:EX
Cc: El Agab, Charlotte S HLTH:EX
Subject: RE: Janssen Inc - follow up to our discussion of Oct. 6th

Hi Barb – thank you for agreeing to meeting with Janssen Inc. After discussions with Charlotte and my VP Julia Brown, we have booked the meeting for next Wednesday, Oct. 28th at 1:00 pm PT. We chose this date/time as you were available and Julia was able as well to join in this meeting.

In attendance will be;

Julia Brown: VP, Market Access, Janssen Inc.
Allan Miranda: Director and Therapeutic Lead, Market Access, Biologic Portfolio
Derek Badger: Government Affairs and Policy, Western Canada.

Jo-Ann

From: Walman, Barbara J. HLTH:EX [<mailto:Barbara.Walman@gov.bc.ca>]
Sent: Friday, October 16, 2015 1:42 PM
To: Stuart Chatterley, Jo-Ann [JOICA]
Cc: El Agab, Charlotte S HLTH:EX
Subject: RE: Janssen Inc - follow up to our discussion of Oct. 6th

Ok.

From: Stuart Chatterley, Jo-Ann [JOICA] [<mailto:jschatt@its.jnj.com>]
Sent: Friday, October 16, 2015 1:30 PM
To: Walman, Barbara J. HLTH:EX
Subject: Re: Janssen Inc - follow up to our discussion of Oct. 6th

Hi Barb - the week of Oct. 19th came from my discussion with DM Brown and was his suggestion. I am out of my own office right now, but will call your office a little later and set up a time that works for both of our organizations.

Thanks Barb.

Jo-Ann

Sent from my iPad

On Oct 16, 2015, at 9:43 AM, Walman, Barbara J. HLTH:EX
<Barbara.Walman@gov.bc.ca> wrote:

Jo-Ann, pls contact my office to set up meeting with respect to portfolios. Is there a particular reason for the week of the 19th?

From: Stuart Chatterley, Jo-Ann [JOICA] [<mailto:jschatt@its.jnj.com>]
Sent: Tuesday, October 13, 2015 7:40 AM
To: Brown, Stephen R HLTH:EX
Subject: Janssen Inc - follow up to our discussion of Oct. 6th

Good morning Stephen – I hope you had a great Thanksgiving weekend.

I am following up to our discussion last Tuesday, Oct. 6th regarding Janssen's biologic portfolio. We had agreed that a meeting with members of your team and Janssen would be appropriate and I know that you had hoped that meeting would happen sometime the week of Oct. 19th. I am emailing to see if you have been able to secure a date and time for that meeting yet?

Thanks again for you time last Tuesday and looking forward to hearing back from you.

Jo-Ann

Jo-Ann Stuart Chatterley
Janssen Inc.
1.800.387.8781 ext 3018 toll free
604.541.9550 direct/604.541.9577 fax/604.765.9553 mobile
jschatt@its.jnj.com



Page 17 to/à Page 19

Withheld pursuant to/removed as

s.21;s.13;s.17

From: [Uyeno, Kelly HLTH:EX](#)
To: [Walman, Barbara J. HLTH:EX](#)
Cc: [Lun, Eric HLTH:EX](#); [Tan, Dominic HLTH:EX](#)
Subject: **s.13,s.17**
Date: Friday, November 27, 2015 4:10:58 PM

Hi Barb,
s.13,s.17

Dom will be calling Derek today with the following messages:
s.13,s.17

· We hope to get back to Janssen later in December

Let us know if you have any questions/concerns. We will continue to complete our formal response to the Janssen proposal.

Thanks,

Kelly

From: [Uyeno, Kelly HLTH:EX](#)
To: [Walman, Barbara J. HLTH:EX](#)
Cc: [El Agab, Charlotte S HLTH:EX](#); [Scott, Pam HLTH:EX](#)
Subject: FW: Faxed Letter from Janssen
Date: Monday, March 21, 2016 4:02:22 PM
Attachments: [Scan_20160321.pdf](#)

FYI. Please disregard if it's a duplicate.

Thanks,

Kelly

Kelly Uyeno

From: Tryan, Derek N HLTH:EX
Sent: Monday, March 21, 2016 3:32 PM
To: Lun, Eric HLTH:EX; Chong, Elaine HLTH:EX; Pang, Walton HLTH:EX; Tan, Dominic HLTH:EX
Cc: Uyeno, Kelly HLTH:EX; Zimmerman, Janine M HLTH:EX
Subject: Faxed Letter from Janssen

We (BMSRS) received this letter via fax from Janssen today, regarding ^{s.21}
s.21

Dominic asked me to scan it and send it out to all of you.

Please see attached

Thanks

Derek Tryan

Executive Assistant, Business Management, Supplier Relations & Systems
Medical Beneficiary & Pharmaceutical Services Division, BC Ministry of Health
301-960 Quayside Drive
New Westminster BC V3M 6G2
Tel: (604) 660-0492
Fax: (604) 660-5405

Warning: This email is intended only for the use of the individual or organization to whom it is addressed. It may contain information that is privileged or confidential. Any distribution, disclosure, copying, or other use by anyone else is strictly prohibited. If you have received this in error, please telephone or e-mail the sender immediately and delete the message.

From: Badger, Derek [JOICA]
To: [Walman, Barbara J. HLTH:EX](#); [Lun, Eric HLTH:EX](#)
Subject: Janssen letter to PMPRB re. Biologic Response Modifier Agent Report
Date: Thursday, November 10, 2016 8:56:27 AM
Attachments: [image001.png](#)
[16-11-07 NPDUIS report PMPRB FINAL Halyk.pdf](#)

Good morning Barbara and Eric,

As an FYI only, sharing the attached letter sent to PMPRB in response to their recent "Market Intelligence Report".

Since the PMPRB Report is cited in the response we got back from s.21
s.21 thought you should be aware of our expressed concerns.

Regards,
Derek Badger
Manager, Government Affairs and Policy
Office: 250.770.1600
Mobile: 250.486.0194



Page 24 to/à Page 28

Withheld pursuant to/removed as

s.21

From: [McClymont, Brenda HLTH:EX](#)
To: [El Agab, Charlotte S HLTH:EX](#)
Cc: [Stevens, Sandy HLTH:EX](#); [Tryan, Derek N HLTH:EX](#); [Maglanque, Joyce HLTH:EX](#)
Subject: 1098544 Janssen Meeting Request - Janssen Inc.
Date: Wednesday, December 13, 2017 2:21:17 PM
Attachments: [1098544 Janssen Meeting Material.docx](#)
[1098544-history.xps](#)

Hi all, Mitch has approved the attached meeting materials for January 12.
Joyce, I've also included the history for your electronic filing.

Thanks

Brenda

From: Stevens, Sandy HLTH:EX
Sent: Thursday, November 23, 2017 11:30 AM
To: El Agab, Charlotte S HLTH:EX
Cc: McClymont, Brenda HLTH:EX; Stevens, Sandy HLTH:EX
Subject: 1098544 Janssen Meeting Request - Janssen Inc.

Hi Charlotte:

Assigned to DIO for mtg. material with a due date to ADMO of Dec 5/17.

Cheers

Sandy

From: El Agab, Charlotte S HLTH:EX
Sent: Thursday, November 23, 2017 9:18 AM
To: McClymont, Brenda HLTH:EX; Stevens, Sandy HLTH:EX
Subject: FW: Meeting Request - Janssen Inc.

Please assign for meeting notes. c

Meeting is in New Westminster on January 12th from 11 to 12 noon.

c

Regards, c

Charlotte El-Agab
Executive Administrative Assistant
to Assistant Deputy Minister, Mitch Moneo
250 952-1464

From: Badger, Derek [JOICA] [<mailto:dbadger@its.inj.com>]
Sent: Monday, November 20, 2017 3:32 PM
To: El Agab, Charlotte S HLTH:EX
Subject: RE: Meeting Request - Janssen Inc.

Good Afternoon Charlotte,

I hope you had a nice weekend.

Just checking to see whether you might have found a suitable date/time. I understand Mr. Moneo was chatting with a couple of my colleagues at a conference in Toronto last week and he has agreed to meet at his earliest convenience.

Thanks very much for your assistance.

Derek

From: Badger, Derek [JOICA]

Sent: Tuesday, November 07, 2017 1:51 PM

To: 'El Agab, Charlotte S HLTH:EX' <Charlotte.ElAgab@gov.bc.ca>

Subject: RE: Meeting Request - Janssen Inc.

Hi Charlotte – here you go. Thanks very much for your assistance.

Date requested:

At the first opportunity that presents itself in Mr. Moneo's calendar.

Time required:

One hour would be requested.

Purpose of Meeting:

s.13,s.17

Suggested Agenda:

Meeting Material:

Janssen will provide a basic slide deck to leave behind as a reference material for Mr. Moneo that covers the main points of our discussion. It will not be necessary to work off the materials in the meeting.

Desired location:

We are happy to meet with Mr. Moneo at either the MBPSD office in Victoria or New Westminster.

Attendees:

Derek Badger
Manager, Government Affairs (BC)

Michael Debolt
Director, Government and Stakeholder Relations (Western Canada)

Julia Brown
Vice President, Government Affairs and Market Access (National)

From: El Agab, Charlotte S HLTH:EX [<mailto:Charlotte.Elagab@gov.bc.ca>]

Sent: Thursday, November 02, 2017 10:53 AM

To: Badger, Derek [JOICA] <dbadger@its.inj.com>

Cc: El Agab, Charlotte S HLTH:EX <Charlotte.Elagab@gov.bc.ca>

Subject: [EXTERNAL] RE: Meeting Request - Janssen Inc.

Hi Derek,

If you can give me the following information, I will do my best to arrange a meeting but fair warning that this will be most likely in the New Year being calendar is totally full.

Date requested:

Time required:

Purpose of Meeting

Agenda

Meeting Material

Desired location:

Attendees:

Thank you

Regards, c

Charlotte El-Agab
Executive Administrative Assistant
to Assistant Deputy Minister, Mitch Moneo
250 952-1464

From: Badger, Derek [JOICA] [<mailto:dbadger@its.jnj.com>]
Sent: Wednesday, November 1, 2017 12:39 PM
To: Moneo, Mitch HLTH:EX
Cc: El Agab, Charlotte S HLTH:EX
Subject: Meeting Request - Janssen Inc.

Dear Mr. Moneo,

Congratulations on your recent appointment to Assistant Deputy Minister, Pharmaceutical Services Division. We have not had the opportunity to engage with you since your appointment and would like to request a meeting at your earliest convenience. The intention would be to better understand your priorities and needs so that we can work to identify areas of mutual alignment with the potential to advance win/win partnership proposals. The purpose is not to circumvent current pan-Canadian processes, but rather to explore viable pathways within that context by which Janssen can re-establish its productive working relationship with MBPSD with the goal of enabling the delivery of practical solutions.

Janssen is Canada's largest pharmaceutical company with a robust product pipeline and research investment footprint. As such, we believe we are uniquely positioned to offer solutions that align with your ministry's priorities s.17

s.17

Thank you, in advance, for your consideration. I look forward to hearing back from you soon regarding your willingness and availability to meet.

Sincerely,

Derek Badger
Manager, Government Affairs
Janssen Inc.
250.486.0194

From: [El Agab, Charlotte S HLTH:EX](#)
To: [Moneo, Mitch HLTH:EX](#)
Subject: FW: Janssen REMICADE Follow Up
Date: Wednesday, April 4, 2018 3:31:25 PM
Attachments: [ADM Mitch Moneo, March 2018.pdf](#)
[image002.png](#)

You did receive this but did you forward to Brenda for cliffing it in?

Regards, c

Charlotte El-Agab
Executive Administrative Assistant
to Assistant Deputy Minister, Mitch Moneo
250 952-1464

From: Badger, Derek [JOICA] [<mailto:dbadger@its.jnj.com>]
Sent: Wednesday, April 4, 2018 3:23 PM
To: El Agab, Charlotte S HLTH:EX
Subject: FW: Janssen REMICADE Follow Up

Hi Charlotte,

I hope you are doing well.

Would you be able to confirm whether Mitch received this letter (see below and attached).

If so, I would welcome the opportunity to answer any questions and/or receive any comments he may have.

Thanks, in advance.

Derek Badger
Manager, Government Affairs
250.486.0194



From: Brown, Julia [JOICA]
Sent: Monday, March 05, 2018 9:47 AM
To: mitch.moneo@gov.bc.ca
Cc: Badger, Derek [JOICA] <dbadger@its.jnj.com>
Subject: Janssen REMICADE Follow Up

Hi Mitch –

I hope this finds you well. Please find attached a letter in follow up to our meeting in January.
Reach out any time if you have questions or would like to discuss.

All the best,

Julia

Julia Brown
Vice President, Government Affairs and Market Access
Janssen Inc.
19 Green Belt Drive
Toronto, ON M3C 1L9
Phone 416-382-4972 Cell 416-305-1854
Fax 416-449-2658
Email jbrown13@its.jnj.com

-



Confidentiality Notice: This e-mail transmission may contain confidential or legally privileged information and is intended only for the individual or entity named in the e-mail address. Any disclosure, copying, distribution, or reliance upon the contents of this e-mail not otherwise authorized by the sender is strictly prohibited. If you have received this e-mail transmission in error, please immediately reply to the sender, so that proper delivery of the e-mail can be effected, and then please delete the message from your Inbox. Thank you.

Page 36

Withheld pursuant to/removed as

s.21

Page 37 to/à Page 38

Withheld pursuant to/removed as

s.21;s.13

Traverse, Chantal HLTH:EX

From: Bouma, Susan HLTH:EX
Sent: Thursday, August 18, 2016 12:19 PM
To: Woo, Dustin HLTH:EX; Gordon, Jason HLTH:EX
Cc: Weston, Megan D HLTH:EX; Pollock, Lynn L HLTH:EX
Subject: RE: UC patient approved for inflectra - urgent

UC is currently reviewed on an exceptional basis at this time and we have indicated the product for which we will cover (exceptionally).

S

From: Woo, Dustin HLTH:EX
Sent: Thursday, August 18, 2016 12:18 PM
To: Gordon, Jason HLTH:EX; Bouma, Susan HLTH:EX
Cc: Weston, Megan D HLTH:EX; Pollock, Lynn L HLTH:EX
Subject: RE: UC patient approved for inflectra - urgent

Yes, this was one of the ones I did in the last two days... I was going to ask how we should proceed in answering this, but put it on the back burner until I finished this morning's meeting minutes

From: Gordon, Jason HLTH:EX
Sent: Thursday, August 18, 2016 11:49 AM
To: Bouma, Susan HLTH:EX; Woo, Dustin HLTH:EX
Cc: Gordon, Jason HLTH:EX; Weston, Megan D HLTH:EX; Pollock, Lynn L HLTH:EX
Subject: FW: UC patient approved for inflectra - urgent

Here is a UC issue re: Inflectra for your consideration!

I am guessing our answer is we approved Inflectra, and not Remicade?

Jason

From: Kelly Loewen [<mailto:kelly.loewen@bioadvancemail.ca>]
Sent: Thursday, August 18, 2016 9:31 AM
To: Gordon, Jason HLTH:EX; Pollock, Lynn L HLTH:EX
Subject: Fwd: UC patient approved for inflectra - urgent

Hi Jason or Lynn

Can you assist while Meghan is away?

Thank you

Kelly Loewen BSc(Pharm) RPh
BioAdvance Coordinator
T: 1-877-783-0454
F: 1-877-783-0454

Begin forwarded message:

From: <kelly.loewen@bioadvancemail.ca>
Date: August 18, 2016 at 9:27:22 AM PDT
To: <Megan.D.Weston@gov.bc.ca>
Subject: UC patient approved for inflectra - urgent

Hi Meghan

Hope you are well
Can you please look into patient s.22
s.22

Application for UC for Remicade and inflectra has been approved

Physician has indicated no sub on the Remicade prescription and inflectra cannot be dispensed

Can you advise ?

Thank you

Kelly Loewen BSc(Pharm) RPh
BioAdvance Coordinator
T: 1-877-783-0454
F: 1-877-783-0454

Traverse, Chantal HLTH:EX

From: Woo, Dustin HLTH:EX
Sent: Wednesday, October 12, 2016 3:06 PM
To: Kaila, Chad S HLTH:EX; Pitt, Katherine L HLTH:EX
Cc: Weston, Megan D HLTH:EX; Woo, Dustin HLTH:EX; Woo, Dustin HLTH:EX
Subject: Infectra vs Remicade approvals for U/C

FYI:

As requested by the Bioadvance coordinators, when we approve Infectra over Remicade for U/C, please put down "Not approved: Remicade" in addition to the Infectra approval.

This is so that they can get coverage through private health plans.

Thank you

Dustin Woo B.Sc.(Pharm)
Pharmacist, Special Authority
Drug Intelligence and Optimization, Medical Beneficiary and PharmaCeutical Services Division
BC Ministry of Health
1515 Blanshard Street
PO box 9562 Stn Prov Govt
Victoria, BC, V8W 9p4

Page 42 to/à Page 43

Withheld pursuant to/removed as

s.22

Traverse, Chantal HLTH:EX

From: Diana Malloch <diana.malloch@bioadvancemail.ca>
Sent: Wednesday, June 14, 2017 1:07 PM
To: Woo, Dustin HLTH:EX
Subject: RE: Emailing: PC approval s.22

Thank you Dustin,
Diana

Diana Malloch, RN
BioAdvance Coordinator
Tel: (855) 474-2877
Fax: (877) 797-1706
Email: diana.malloch@bioadvancemail.ca

This e-mail is a confidential communication from BioAdvance. If you are not the intended recipient of this message please notify us immediately by return e-mail. After notification please delete this message and any attachments and/or paper copies that may have been created

-----Original Message-----

From: Woo, Dustin HLTH:EX [<mailto:Dustin.Woo@gov.bc.ca>]
Sent: June-14-17 12:45 PM
To: Diana Malloch
Cc: Woo, Dustin HLTH:EX
Subject: RE: Emailing: PC approval s.22

This will go to cmte for renewal. Yes, if its maintenance, then it should choosing that option should work.

-----Original Message-----

From: Diana Malloch [<mailto:diana.malloch@bioadvancemail.ca>]
Sent: Wednesday, June 14, 2017 12:29 PM
To: Woo, Dustin HLTH:EX
Subject: Emailing: PC approval s.22

Your message is ready to be sent with the following file or link attachments:

PC approval s.22

Note: To protect against computer viruses, e-mail programs may prevent sending or receiving certain types of file attachments. Check your e-mail security settings to determine how attachments are handled.